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ABSTRACT c-Jun trcriptional activity is augmented
by expression of oncogenic Ras and Raf proteins. This study
demonstrates a direct correlation between Ras tAsfom
activity and c-Jun activation, s ing an Imprnt role for
c-Jun in tsfor by Ras. Since we observed that Ras
activated c-Jun trarIptinal activit by in sing phos
phorylation of the c-Jun activation domain at residues Ser-63/
Ser-73 and that icRas proteins activated extracellular
signal-regulated protein ka (ERK1 and ERK2) (also
known as mit -activated protein kiass), we evaluated the
possibity that ERKs were dlrectly responsible for c-Jun
activation. Coexpresson ofwild-typeERKs with oncogenic Ras
proteins potentiated, while Dasdefective ERKs inhibited,
Ras-Induced taitonlvation from the Ras-respon-
sive element (Etsa-/AP-i) present in the NVL-3 enhancer and
the serum-response element in the c-fos promoter. In contrat,
coexpresslon of either wild-type or kinase-defective ERKs
inhibited Ras and Rat activation of c-Jun transcriptional
activty Thus, although activation of both ERK and c-Jun are
downstream consequences of activation of the Ras signal trans-
duction pathway, our results suggest that Ras-induced c-Jun
phosphorylation and transcriptional activation are not a direct
consequence of ERK1 and ERK2 activation.
The human Ras proteins (H-, N-, and KRAS) function as
critical regulators of signal transduction pathways triggered
by diverse extracellular signals (1-3). The ligand-triggered
autophosphorylation ofreceptor tyrosine kinases on tyrosine
residues recruits the Ras exchange factor SOS to the plasma
membrane via the GRB2 adapter protein, leading to stimu-
lation of Ras GDP/GTP exchange and activation of Ras (4).
Ras transforming potential is activated by mutations that
cause either reduced intrinsic or GTPase-activating protein
(GAP)-stimulated GTPase activities (at residues 12, 13, and
61) or enhanced nucleotide exchange rates (e.g., at residues
116-119 and 146) (3, 4). Activated GTP-Ras (5-7) associates
with Raf(8-12). The activated Rafkinase phosphorylates and
activates mitogen-activated protein (MAP) kinase/extracel-
lular signal-regulated protein kinase (ERK) kinases, which in
turn activate ERK1 and ERK2 (5-7, 13).
Genes containing certain DNA sequence motifs (e.g., Ets,
AP-1, and NFKB) are preferentially activated by oncogenic
Ras proteins, implicating members of the Ets, Jun, Fos, and
Rel families of transcription factors as possible mediators of
Ras function (6). Consistent with the involvement of these
transcription factors in Ras transformation are observations
that dominant-inhibitory mutants of Ets-1 and c-Jun are also
potent inhibitors of oncogenic Ras transformation (13-15).
There is strong evidence that ERKs phosphorylate the
transcriptional activation domain ofc-Myc in vitro (16) and in
vivo (16, 17), resulting in its enhanced transcriptional activity.
A similar type ofanalysis demonstrated that the transcription
factor Elk-i (TCF-1), which participates in formation of a
protein complex that binds to the serum response element of
c-fos, is phosphorylated by ERKs, enha g its transcrip-
tional activity (18, 19). ERKs also phosphorylate c-Jun in
vitro, but the specific phosphorylation sites and the physio-
logical sequelae are unclear. Although some reports state that
c-Jun phosphorylation by ERKs occurs within the c-Jun
activation domain (20, 21), indicating that ERKs may be the
c-Jun-activating kinase(s) (JNK), other studies have reported
instead that ERKs phosphorylate the C-terminal DNA bind-
ing domain of c-Jun (22-24) so that the c-Jun-activating
kinase must be distinct from ERKs.
Oncogenic Ras(61L) and v-Rafproteins activate ERKs and
stimulate transcriptional activity ofc-Jun by increasing phos-
phorylation of Ser-63 and -73 within the c-Jun activation
domain (25-27). Recently, a JNK, which phosphorylates
these sites, was purified (28). However, the relationship
between JNK and ERKs needs to be clarified. Our results
demonstrate a direct correlation between Ras transforming
activity and c-Jun activation. This study further demon-
strates that although mutant Ras proteins stimulate ERK
activity, the signal transduction pathway for the activation of
c-Jun does not directly include ERKs.
MATERIALS AND METHODS
Cell Culture. NIH 3T3 cells were grown in DME high
glucose medium (GIBCO) supplemented with 10% calfserum
(Colorado Serum, Denver). DNA transfections were done as
described (29).
Plsmids. pGEX2T-cJun(wt), pGEX2T-cJun(Ala-63, -73),
p20-Luc, Gal4-cJun, Gal4-cJun(AA), and the 5xGal-Luc
were described (28). Gal4-cJun expresses the Gal4 DNA-
binding domain linked to amino acids 1-246 ofhuman c-Jun.
Gal4-cJun(AA) has Ser-63 and Ser-73 of c-Jun mutated to
aianines. Gal4-ElkC contains the Gal4 DNA binding domain
linked to the Elk-1 transactivation domain (18). 5xGal-Luc
contains 5 consensus Gal4 DNA binding sites (17-mers)
subcloned into p20-Luc. All pZIP-Ras constructs have been
described (30). p22W-Rafcontains an activated form ofRaf-1
(31). ERK cDNAs and mutants (32, 33) were subcloned into
the expression vector pCMV5. Col3-Luc contains the colla-
gen al(I) promoter (34). Fos-Luc contains the human c-Fos
promoter (35). RD053-Luc contains a sequence from the
murine NVL-3 long terminal repeat that confers responsive-
ness to both phorbol 12-myristate 13-acetate and activated
Ras (36). RD053(Al)-Luc, an AP-1 site mutated version of
Abbreviations: MAP kinase, mitogen-activated protein kinase;
ERK, extracellular signal-regulated protein kinase; GST, glutathione
S-transferase; JNK, c-Jun-activating kinase; MBP, myelin basic
protein; RRE, Ras-responsive element; GAP, GTPase-activating
protein.
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RD053, and RDO53(El)-Luc, an Ets-1 site mutated version
of thp same reporter, were provided by M. Ostrowski (Duke
University).
Transfections and Luciferase Assays. Transient transfection
assays used 2.5 pug of reporter plasmid, 250 ng of expression
vector (if used), 250 ng of cotransfected Ras plasmids, and
100 ng of cotransfected ERK constructs (if used). In some
experiments, 0.5 pg of pSV2Gal (Promega) was added as an
internal control of transfection efficiency. Thirty hours post-
transfection, cells were washed with phosphate-buffered
saline and lysed in 200 1d of luciferase lysis buffer (0.1 M
sodium phosphate, pH 7.8/0.5% Triton X-100/1 mM dithio-
threitol).
Cell Extracts. Extracts were prepared as described (37)
with the addition of the following inhibitors in all buffers: 500
mM phenylmethylsulfonyl fluoride, 2 mg of aprotinin per ml,
0.5 mg of leupeptin per ml, 0.7 mg of pepstatin per ml, 40 mg
ofbestatin per ml, 20mM glycerophosphate, 50mM Na3VO4,
10 mM p-nitrylphenyl phosphate.
In Vitro JNK Assays. In vitro kinase assays were carried out
as described (28) using a glutathione S-transferase (GST)-c-
Jun(1-223) fusion protein as substrate.
ERK Assays. For the mobility-shift ERK assays, 5 pug of
each cell extract was mixed with 2x sample buffer (38),
boiled briefly, and electrophoresed through a low cross-
linker 12.5% polyacrylamide gel. Proteins were transferred to
Immobilon membranes (Millipore) for analysis by Western
blotting with an anti-MAP kinase antibody (691 rabbit poly-
clonal, Santa Cruz Biotechnology) and the ECL detection
system (Amersham). For the in-gel kinase assays, myelin
basic protein (MBP) was used as a substrate (39) with 25 pg
of each cell extract. Radioactivity was visualized by Ambis
3 scanning.
Cel Ing and Inuuno pati. Labeling and im-
munoprecipitation of c-Jun were performed as described (40)
with antiserum provided by A. Kraft (University ofAlabama).
Two-Dnsnal Pospopeptide Mapping. Protein elution
and trypsin treatment were performed as described (41).
Cellulose plates were loaded with equal amounts of immu-
noprecipitated protein, and two-dimensional phosphopeptide
mapping of c-Jun was performed as described (40, 42).
RESULTS
Oncogenic Ha-Ras Induces Hyperphosphorylation of the
c-Jun Transactivation Domain by Stiulatg c-Jun Kinase
Activity. Previous studies have demonstrated that oncogenic
Ha-Ras(61L) stimulates phosphorylation of the c-Jun activa-
tion domain, resulting in increased c-Jun transcriptional
activity (25-27). To determine whether other forms of onco-
genic Ras have similar activity, we examined c-Jun phos-
phorylation in NIH 3T3 cells and NIH 3T3 cells stably
transfected with Ha-Ras(12R). Ha-Ras(12R) expression re-
sulted in hyperphosphorylation of c-Jun, as demonstrated by
a slower mobility form ofJun in [35S]methionine-labeled cells
and by increased 32p; incorporation (Fig. 1A). Synthesis of
total c-Jun protein in these cells was increased by transient
cotransfection of a c-Jun expression vector and was elevated
only slightly by the presence of Ha-Ras(12R) (Fig. 1A).
Two-dimensional phosphopeptide maps demonstrated that
Ha-Ras(12R) transformation caused increased phosphoryla-
tion of Ser-63 and Ser-73 of c-Jun as indicated by the
increased intensity of the x and y phosphopeptides (25, 26),
while no effect on the C-terminal sites was detected (Fig. 1B).
Radioactivity quantitation of the x site normalized for the
C-terminal sites demonstrated an 18-fold increase for the
Ha-ras(12R) cells [x/(a + b + c) = 1.27] compared to the
control NIH 3T3 cells [x/(a + b + c) = 0.07]. Therefore,
Ha-Ras(12R) transformation leads to hyperphosphorylation
of c-Jun in a manner similar to that of the previously
described effect of Ha-Ras(61L).
We wished to determine whether Ras-induced phosphor-
ylation of c-Jun resulted from increased JNK activity or
decreased phosphatase activity. To assay for JNK activity,
we used a previously described solid-state assay (28). Im-
mobilized GST-c-Jun protein was incubated with nuclear
extracts prepared from NIH 3T3 cells that expressed differ-
ent mutant Ras proteins. Whereas no increase in JNK
activity was observed in cells expressing the unprocessed
Ha-Ras(61L/186S) mutant protein, increased JNK activity
was detected in cells expressing oncogenic Ha-Ras(61L),
-(12R), or -(61P) mutant proteins (Fig. 2). As controls, a
recombinant GST protein without the c-Jun activation do-
main was used as a substrate without any resulting phos-
phorylation (Fig. 2A). A recombinant GST-Jun fusion pro-
tein in which the Ser-63 and Ser-73 amino acids were mutated
to alanines was phosphorylated to a lower extent than
wild-type GST-c-Jun (Fig. 2).
There Is a Direct Correlation Between Transformation Ef-
ficiency and c-Ju Transcriptional Activity. To determine the
functional significance of increased c-Jun phosphorylation in
response to a variety of Ras proteins, we used a cotransfec-
tion assay to measure the transcriptional activity of the c-Jun
activation domain. In this assay, NIH 3T3 cells were tran-
siently transfected with a Ras expression vector, a chimeric
expression vector containing the Gal4 DNA binding domain
















FIG. 1. The c-Jun activation domain is hyperphosphorylated in
Ha-Ras(12R) transformed cells. Normal NIH 3T3 cells (3T3) or
Ha-Ras(12R) transormed NIH 3T3 cells (12R) were transfected with
a c-Jun expression vector and labeled with 32P (Left) or P5S]methio-
nine (Right). Cell lysates were immunoprecipitated with c-Jun-
specific antiserum. (A) Proteins were separated by SDS/PAGE,
followed by blotting to nitrocellulose and exposure to film for 3 hr.
Position ofthe c-Jun protein is indicated. The slower electrophoretic
mobility forms result from phosphorylation. (B) 32P-labeled c-Jun
proteins from A were treated with trypsin and eluted from the
nitrocellulose. Equal amounts of trypsin-treated protein were sub-
jected to thin-layer electrophoresis in the horizontal dimension
(cathode at the right) and chromatography in the vertical dimension.
Origin is on the lower left of each map. Plates were exposed for 18
hr at -850C with an intensifying screen. Peptides x (containing
phosphoserine-73) and y (containing phosphoserine-63) and a, b, c
(phosphopeptides adjacent to the DNA-binding domain) are indi-
cated.
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FIG. 2. Activation of a JNK in Ras-transformed cells. Ten
nanograms of recombinant GST protein, GST-Jun (wild-type c-Jun,
aa 1-223), or GST-Jun(A63,73) (Ser-63 and -73 mutated to Ala) was
used as substrate to measure JNK (28) with 50 Mg of nuclear extract
prepared from NIH 3T3 cells or from NIH 3T3 cell lines stably
transformed with wild-type or mutant Ha-Ras proteins. (A) GST or
GST fusion proteins were incubated with nuclear extracts prepared
from wild-type Ha-Ras-transformed cells (lanes 1, 2, and 4), parental
NIH 3T3 cells (lane 3), Ha-Ras(61L/186S) (lane 5), and Ha-Ras(61L)
(lane 6). (B) In a separate experiment, the indicated substrates were
incubated with extracts prepared from Ha-Ras(12R)-transformed
cells (lanes 1 and 3), parental 3T3 cells (lane 2), Ha-Ras(61P) cells
(lane 4), and Ha-Ras(61L) cells (lane 5). Single band in each lane
represents phosphorylated GST-Jun as in A.
luciferase reporter gene containing five Gal4 DNA binding
sites (5xGal-Luc). For each of the Ras genes (N-, Ki-, and
Ha-Ras), the transforming Ras proteins demonstrated a
markedly greater stimulation of the activation domain of
c-Jun than the nontransforming Ras proteins (Table 1). The
inability of the nontransforming Ha-Ras(61L/186S) mutant
protein to activate c-Jun demonstrates that posttranslational
processing and membrane association are required for trans-
forming activity. The absence of activity observed with a
nontransforming mutant Ras protein contaiing a mutation in
the Ras effector domain (35A/61L) indicates that interaction
with Raf-1, NF1-GAP, and/or p120 GAP is required for
Ras-induced c-Jun activation. For each Ras protein, there
was a direct correlation between stimulating c-Jun transcrip-
tional activity and transforming activity, as measured by
focus formation in NIH 3T3 cells (R2 = 0.874; P < 0.0002).
Thus, the activation of JNK, which is responsible for stim-
ulation of c-Jun activity (28), is a potent predictor of Ras
transforming potential.
Oncogenic Ras Proteins Stimulate ERK Activity. Next, we
examined whether ERKs are activated in parallel with JNK.
Like JNK, ERKs were activated in transformed, but not in
untransformed, NIH 3T3 cells (Fig. 3). Western blotting of
extracts prepared from cells transformed by the oncogenic Ras
proteins Ha-Ras(61L), Ha-Ras(12R), and Ha-Ras(61P) dem-
onstrated the presence of the phosphorylated active forms of
ERKs (Fig. 3A), whereas parental NIH 3T3 cells or those
expressing the nontransforming effector domain mutant Ha-
Ras(35A/61L) contained only the nonphosphorylated inactive
forms. To confirm that the mobility shift seen by Western
Table 1. Biochemical and biological activities of Ras mutants
Ras mutant and Relative FFUt c-Jun activation*
substitution(s)* [Ha-ras(61L) = 1.0] (no Ras protein = 1.0)§
None 0.00 1.0
Ha-Ras
Normal 0.00 1.41 ± 0.04
12R 0.80 5.31 ± 1.15
13V 0.92 3.31 ± 0.44
59T 0.90 3.37 ± 0.77
61L 1.00 5.58 ± 1.11
61P 0.09 1.85 ± 0.51
61W 0.46 3.45 ± 0.98
35W/61L 0.00 0.54 ± 0.22
35A/61L 0.00 0.99 ± 0.65
61L/186S 0.00 0.% ± 0.30
116H 0.14 1.69 ± 1.08
117E 0.83 3.77 ± 0.85
119E 0.01 1.03 ± 0.09
N-Ras
Normal 0.00 1.95 ± 0.78
12D 1.15 5.44 ± 1.88
Ki-Ras 4B
Normal 0.00 0.81 ± 0.20
12V 0.71 5.26 ± 1.42
*Amino acid substitution(s) in normal Ras protein.
tFocus-forming units: values are averages of at least three experi-
ments performed in quadruplicate.
tExpressed as -fold induction of the SxGal-Luc reporter gene (2.5
Mg) by the SVGal-Jun expression vector (250 ng) plus the indicated
Ras mutant (250 ng) in transient transfection assays. Values are
means ± SEM and are from at least three experiments performed
in duplicate and normalized for transfection efficiency.
IBasal stimulation of5xGal-Luc by SVGal-Jun in the absence ofRas
coexpression averaged 54-fold over several experiments.
blotting correlated with activation of ERK kinase activity,
in-gel kinase assays were performed. Extracts oftransformed,
but not nontransformed, NIH 3T3 cells containedERK kinase
activity capable ofphosphorylating a MBP substrate incorpo-
rated into the gel (Fig. 3B). Thus, only oncogenic forms of
Ha-Ras constitutively activate ERKs. The absence ofactivity
with the Ha-Ras(35A/61L) mutant indicates that an intact
effector domain is required for Ras signaling through ERKs.
These results prompted our assessment ofwhether transform-
ing Ras genes activate c-Jun through ERKs.
Ras Stmulates ERK and c-Jun Transcriptioal Activity by
Distinct Pathways. To address the relationship between ERK
and c-Jun activation, we investigated whether expression of
exogenous wild-type or kinase-deficient ERKs influenced
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FIG. 3. Constitutive activation of ERKs in Ras-transformed
cells. Extracts prepared from NIH 3T3 cells stably transformed by
mutant Ha-Ras proteins were Western blotted and probed for
inactive and active forms of ERKs (A) or used as a source ofERK
activity in an in-gel MBP kinase assay (B). (A) Arrows, inactive,
unphosphorylated forms of ERK1 and ERK2; asterisks, active
phosphorylated forms of ERK1 and ERK2. Shown are extracts
prepared from parental NIH 3T3 cells (lane 1) or from NIH 3T3 cells
expressing oncogenic Ha-Ras mutants 61L (lane 2), 12R (lane 3), 61P
(lane 4), or an effector domain mutant 35A/16L (lane 5). (B)
Twenty-five micrograms of cell extracts from parental NIH 3T3 cells
(lane 1) or from cells expressing Ha-Ras(61L) (ane 2), Ha-Ras(12R)
(lane 3), Ha-Ras(61P) (lane 4), or Ha-Ras(wt) (lane 5).
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pression of wild-type ERKs might enhance c-Jun activation,
whereas the kinase-deficient mutants K71R-ERK1 and
K52R-ERK2 (33) might function as dominant negative forms
ofERKs to cause inhibition ofRas-induced c-Jun activation.
In the absence of activated Ras, both wild-type and mutant
ERK expression vectors inhibited basal c-Jun transcriptional
activity as assayed with the 5xGal4-Luc reporter gene and
Gal4-Jun expression vector (Fig. 4A). Unexpectedly, coex-
pression of either wild-type ERK1 or ERK2 expression
vector in the presence of activated Ras resulted in marked
inhibition of c-Jun transcriptional activity when compared to
its stimulation by Ras alone (Fig. 4A). Coexpression of the
mutant ERKi or ERK2 expression vector resulted in a
greater inhibition of c-Jun transcription activity (Fig. 4A).
Similarly, both wild-type and mutant ERKi also inhibited
c-Jun activation by oncogenic Raf (Fig. 4B) (43). These
results suggested that activated ERKs are not directly in-
volved in c-Jun or JNK activation.
An alternative explanation for the inhibitory activities of
both wild-type and mutant ERKs is that overexpression of
either form caused an inhibition ofERK function or that their
overexpression was growth inhibitory. In the first control












































FIG. 4. Activation of reporter gene
type or mutant ERK expression ve
transfected with 2.5 jmg ofthe indicated
of a vector expressing no Ras protc
Ha-Ras(61L) expression vector. In add
(pCMV5) or expression vector for wild
or kinase-deficient ERK1 (KRERK1, v
kinase-deficient ERK2 (KS2RERK2),
plate. Results in B-E were normalize
activity to allow direct comparison of
gions. RLU, relative luciferase units.
promoter driving the luciferase gene (Col3-Luc), which is not
responsive to activated Ras genes (44). In the absence or
presence of activated Ras, neither the wild-type nor the
kinase-deficient ERK expression vector had a significant
effect on Col3-Luc (Fig. 4C).
The c-fos promoter contains a serum response element, on
which factors including the serum response factor and Elk-i
combine to form a ternary complex. Elk-i is a substrate for
ERKs and phosphorylation of Elk-i enhances its transcrip-
tional activity (18). As expected, wild-type ERK expression
vectors enhanced the activation ofFos-Luc by activated Ras,
while the mutant ERKs inhibited activation by Ras (Fig. 4D).
Furthermore, wild-type but not kinase inactive ERK1 en-
hanced Ras activation of a Gal-ElkC chimeric transcription
factor (18) using the same reporter and expression vector
concentrations as in Fig. 4A (data not shown).
Finally, we evaluated the relationship between ERKs and
Ras signal transduction by using the murine NVL-3 long
terminal repeat Ras-responsive element (RRE), consisting of
overlapping AP-M and Ets-i binding motifs (36). In the
absence of a Ras expression vector, both the wild-type and
kinase-inactive ERK expression vectors had a minimal effect
on transcriptional activity from the RRE Luc reporter (Fig.
4 E and F). As expected, cotransfection with Ha-Ras(61L)
stimulated RRE Luc activity. This activity was further en-
hanced by cotransfection of the wild-type ERK1 or ERK2
expression vector. On the other hand, cotransfection of the
ERK1 kinase-deficient mutant vector had a slight inhibitory
effect on reporter gene activity, while the kinase-inactive
ERK2 vector had no effect. A 2-base mutation in the AP-M
motif (AP-imut) or in the Ets-i motif (Ets-imut) of the RRE
attenuated basal expression and stimulation by both Ras and
ERK proteins (Fig. 4F). These results suggest that ERKs are
critical intermediates between Ras and activation of com-
posite AP-1/Ets-1 binding sites.
DISCUSSION
* pCMV5 Although Ras proteins have long been implicated as critical
intermediates in signal transduction pathways that dictate
s Erk +kErk2 cell growth and differentiation (1, 3), only recently have the
0 K52RErk2 essential components ofthe Ras signaling pathway, and their
functional associations, been elucidated (2-5, 8-12, 45, 46).
However, the details of the pathway beyond ERKs, and the
identity of the downstream substrates for ERK phosphory-
lation, which are important for Ras-induced cellular trans-
zipnec zipHa-Ras(L61) formation, remain unresolved (6). Since c-Jun phosphoryla-
RRE-Luc tion and activation have been observed in Ras-transformed
F n pCMVS cells (25, 26), and since c-Jun cooperates with Ras in onco-
l Erkl genic transformation (47), c-Jun represents a strong candi-
0] KRErkI date for an essential component of the Ras signal transduc-
tion pathway. Therefore, we investigated the relationship
between Ras transforming activity and the activation of
ERKs and c-Jun.
The transcriptional activity of c-Jun is regulated by its
_il___Li phosphorylation status. Phosphorylation of the N-terminal
:D CZ Dt transactivation domain at Ser-63 and Ser-73 results in in-
U X E - creased transcriptional activity (25-27). In contrast, phos-
phorylation near the DNA binding domain results in de-
W creased DNA binding and, consequently, decreased tran-
z< LU scriptional activity (23, 40). The previous observations that
both activated Ha-Ras(61L) and v-Raftrigger hyperphospho-
es by cotransfection of wild- rylation of Ser-63 and -73 implicated a role for c-Jun activa-
ctors. NIH 3T3 cells were tion via Ser-63/73 phosphorylation in Ras-induced transfor-
reporter plasmids plus 250 ng mation. In this study, we assayed c-Jun activation by a series
Hin (pZlPneo) or 250 ng of ofRas mutant proteins that vary widely in their transforming
-tion, 100 ng of empty vector potential, and observed a strong direct correlation between
ith a mutation at residue 71): Ras transforming potential and c-Jun activation. This further
or both, was transfected per implicates hyperphosphorylation ofc-Jun at Ser-63 and -73 as
d for P-galactosidase (8Gal) critical events required for Ras-induced transformation.
f the promoter/enhancer re- We observed that kinase-deficient ERKs (32, 33, 48) inhib-
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FIG. 5. Schematic representation of a Ras signal transduction
pathway. RTK, receptor tyrosine kinase; SRE, serum response
element.
RRE. Experiments with higher concentrations of the kinase-
deficient ERK plasmids produced greater inhibition (data not
shown). Thus, ERKs appear to be essential intermediates in
signaling pathways that control certain Ras-responsive genes.
When we examined the role of ERKs in regulating c-Jun
transcriptional activity, we observed strikingly different re-
sults. In these experiments, both the wild-type and, to a
greater extent, the kinase-deficient ERKs inhibited the signal
transduction pathway from Ras or Raf to c-Jun activation.
This inhibition of Ras-induced c-Jun activation by both
wild-type and mutant ERKs was observed over a wide range
of concentrations and times (data not shown). The use of the
chimeric Gal-Jun transcription factor enabled us to assess the
activation of c-Jun independently of other AP-1 transcription
factors, such as c-Fos, which is activated by ERKs. There-
fore, enhanced ERK expression did not augment the activa-
tion of c-Jun by Ras or Raf. The simplest interpretation of
these data is that the activation of c-Jun by Ras does not
directly involve the ERKs but that there are common ele-
ments in both pathways extending downstream to Raf, while
the role of MAP kinase/ERK kinases (MEK) is unknown
(Fig. 5). At least one common element may be absorbed by
overexpression of wild-type and kinase-deficient ERKs,
thereby blocking the signal transduction pathway leading to
c-Jun activation. Thus, the final effect of activated Ras on
gene transcription represents the net interaction of sequential
and parallel kinase cascades.
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